Lupus, a nasty and mysterious disease, has proved impervious to yet another drug.
This time it’s Rituxan, co-marketed by Genentech and Biogen Idec and already approved for cancer and rheumatoid arthritis, which is, like lupus, an autoimmune disease. The companies said this morning that Lupus patients in a large trial of the drug fared no better [...]
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment